Citation Impact
Citing Papers
Cell wall α‐1,3‐glucan is required to anchor the Cryptococcus neoformans capsule
2003
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
2010 Standout
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages
2001
Phagosome Extrusion and Host-Cell Survival after Cryptococcus neoformans Phagocytosis by Macrophages
2006
Advances in combating fungal diseases: vaccines on the threshold
2006
Opening the microcirculation: can vasodilators be useful in sepsis?
2002
Neurocysticercosis: An Update
1988
Antibodies Elicited by a Cryptococcus neoformans-Tetanus Toxoid Conjugate Vaccine Have the Same Specificity as Those Elicited in Infection
1992
Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice
1992
Taenia solium cysticercosis
2003 Standout
Guideline for Prevention of Surgical Site Infection, 1999
1999 Standout
Guideline for hand hygiene in health-care settings
2002 Standout
Biological roles of glycans
2016 Standout
Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome
1991
Preoperative skin preparation and surgical outcome
1988
Role of the Environment of the Operating Suite in Surgical Wound Infection
1991
Guideline for Hand Hygiene in Health-Care Settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force
2002 Standout
Chapter 26 Reduced neuronal activity and reactivation in Alzheimer's disease
1998
Skin Hygiene and Infection Prevention: More of the Same or Different Approaches?
1999 Standout
Sepsis and septic shock
2018 Standout
Spleen deposition ofCryptococcus neoformanscapsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1
2008 StandoutNobel
Practice Guidelines for the Management of Cryptococcal Disease
2000 Standout
Cas1p is a membrane protein necessary for the O‐acetylation of the Cryptococcus neoformans capsular polysaccharide
2001
Immunity to fungal infections
2011 Standout
Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination
1993 Standout
Soluble Polysaccharides of Cryptococcus neoformans
1988
GRAM-NEGATIVE BACILLI ON THE SKIN*
1969
Pseudomonas aeruginosaEpidemic Traced to Delivery-Room Resuscitators
1967
Differential diagnosis between ventriculitis and fourth ventricle cyst in neurocysticercosis
1983
A Yeast under Cover: the Capsule ofCryptococcus neoformans
2003
Infections of the Central Nervous System Due to Pseudomonas Aeruginosa
1969
Hydrocephalus in cerebral cysticercosis
1981
Guideline for Prevention of Surgical Site Infection, 1999
1999 Standout
The epidemiological significance of Pseudomonas aeruginosa in hospital sinks.
1976
Virulence factors of medically important fungi
1996
The Capsule ofCryptococcus neoformansReduces T-Lymphocyte Proliferation by Reducing Phagocytosis, Which Can Be Restored with Anticapsular Antibody
1999
What is cognitive reserve? Theory and research application of the reserve concept
2002 Standout
Comparison of 5.8S ribosomal DNA sequences among the basidiomycetous yeast generaCystofilobasidium, FilobasidiumandFilobasidiella
1992
Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
2003 Standout
Surgical considerations in treatment of intraventricular cysticercosis
1984
Hemicelluloses
2010 Standout
Aspergillus fumigatusand Aspergillosis
1999 Standout
Guidelines for Preventing Health-Care-Associated Pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee
2004 Standout
Hybridization probes for conventional DNA fingerprinting used as single primers in the polymerase chain reaction to distinguish strains of Cryptococcus neoformans
1993
Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody
1990
Etiology and Pathogenesis of Temporal Lobe Epilepsy
1964
Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans
1991
Molecular typing of Cryptococcus neoformans serotype D clinical isolates
1994
Focal dysplasia of the cerebral cortex in epilepsy
1971 Standout
Acanthamoebaspp. as Agents of Disease in Humans
2003 Standout
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
1995 Standout
Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee.
1999 Standout
Genetic and Related Aetiological Factors in Temporal Lobe Epilepsy
1971
Galleria mellonella as a Model System To Study Cryptococcus neoformans Pathogenesis
2005 Standout
Killing of Cryptococcus neoformans strains by human neutrophils and monocytes
1991
Phagocytosis and Killing of Cryptococcus neoformans by Rat Alveolar Macrophages in the Absence of Serum
1989
Works of J. M. Small being referenced
Prolonged hemorrhagic shock decreases splanchnic prostacyclin synthesis
1991
CYSTICERCOSIS OF THE POSTERIOR FOSSA
1956
FATAL DAMAGE TO THE BRAIN BY EPILEPTIC CONVULSIONS AFTER A TRIVIAL INJURY TO THE HEAD
1957
Strain variation in composition and molecular size of the capsular polysaccharide of Cryptococcus neoformans serotype A
1986
Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A
1989
Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants
1986
HOSPITAL INFECTION WITH PSEUDOMONAS ÆRUGINOSA IN NEUROSURGERY
1965
HYPERSOMNIA IN DYSTROPHIA MYOTONICA
1961